What Is Retatrutide? The Triple-Agonist Changing Weight Loss in 2026 — Rewind Anti-Aging of Miami
← Back to Blog
weight loss · 10 min read

What Is Retatrutide? The Triple-Agonist Changing Weight Loss in 2026

Retatrutide is the most powerful weight loss peptide in 2026 — a triple-agonist targeting GLP-1, GIP, and glucagon. How it works, the clinical data, and where to get it in Miami.

By the Rewind medical team
Medically reviewed by Alexia Padron, MSN, APRN, FNP-BC ·
Share:

If you have been following medical weight loss, you know the names: semaglutide, tirzepatide, Ozempic, Wegovy, Mounjaro, Zepbound. These medications have produced results that were genuinely unthinkable a decade ago — 15 to 22 percent body weight loss from a once-weekly injection, without bariatric surgery and without extreme calorie restriction.

But there is a newer compound generating even more excitement among researchers and clinicians — retatrutide. It targets three metabolic pathways instead of one or two, and in Eli Lilly’s trials adults on the 12 mg dose lost an average of 24.2 percent of body weight in 48 weeks (Phase 2) and 28.3 percent in 80 weeks (Phase 3 TRIUMPH-1).

This article explains exactly what retatrutide is, how it works, what the data actually shows, and why most Miami clinics are not yet offering it.

How Retatrutide Works: The Triple-Agonist Advantage

To understand why retatrutide produces larger weight loss results than its predecessors, you need to understand the three metabolic pathways it activates simultaneously.

GLP-1 Agonism — The Appetite Pathway

GLP-1 (glucagon-like peptide-1) is the incretin hormone that semaglutide targets. When you activate GLP-1 receptors, several things happen: appetite is suppressed through signaling in the hypothalamus and brainstem, gastric emptying slows, insulin release becomes more glucose-responsive, and inappropriate glucagon release after meals is reduced. The result is less hunger, smaller portions, and better blood sugar regulation.

This is the core mechanism behind every GLP-1 medication on the market. It works — semaglutide produced approximately 14.9 percent body weight loss in the STEP 1 trial. But it works primarily by reducing caloric intake.

GIP Agonism — The Metabolic Efficiency Pathway

GIP (glucose-dependent insulinotropic polypeptide) is a second incretin hormone that tirzepatide adds to the GLP-1 pathway. GIP enhances insulin sensitivity, influences how fat is stored and metabolized in adipose tissue, and works synergistically with GLP-1 to amplify appetite suppression.

Adding GIP to GLP-1 is what allowed tirzepatide to outperform semaglutide in head-to-head trials, producing approximately 22.5 percent weight loss in the SURMOUNT-1 trial compared to semaglutide’s 14.9 percent. Two pathways are better than one.

Glucagon Agonism — The Fat-Burning Pathway

The glucagon pathway is where retatrutide separates itself from every other weight loss medication currently available or in late-stage development.

Glucagon is a hormone produced by the alpha cells of the pancreas. Its conventional role is to raise blood sugar when levels drop too low, but it has another effect that is critical for weight management: it promotes fat oxidation in the liver (beta-oxidation). In retatrutide’s Phase 2 liver substudy, a blood marker of fat burning rose two- to threefold on doses of 4 mg and higher (3). In obese mice, adding the glucagon arm increased energy expenditure on top of reduced food intake (1).

Why Three Pathways Outperform Two

Semaglutide reduces the input side of the energy balance equation. Tirzepatide reduces input more efficiently. Retatrutide reduces input and adds a pathway aimed at stored fat, starting with the liver. The simplest way to think about it: semaglutide and tirzepatide help you eat less. Retatrutide helps you eat less and break down stored fat.

In its own trials, that combination produced larger average weight loss than the dual-agonist’s trials did.

The Clinical Data

Woman in her fifties delighted to zip up a dress she hadn't worn in years

Phase 2 Trial Results (Jastreboff et al., NEJM 2023)

The landmark Phase 2 trial of retatrutide enrolled 338 adults with obesity or overweight with a weight-related condition. Participants were randomized to retatrutide at 1, 4, 8, or 12 mg weekly or to placebo for 48 weeks (2). The results:

  • 12 mg dose: Average weight loss of 24.2 percent of body weight
  • 8 mg dose: Average weight loss of 22.8 percent
  • 4 mg dose: Average weight loss of 17.1 percent
  • Placebo: Average weight loss of 2.1 percent

On the 12 mg dose, every participant lost at least 5 percent of body weight, 93 percent lost at least 10 percent, and 83 percent lost at least 15 percent.

Phase 3 Trial Results (TRIUMPH-1, 2026)

Longer treatment produced more. In TRIUMPH-1, 2,339 adults with obesity or overweight and no diabetes were treated for 80 weeks (4):

  • 12 mg dose: Average weight loss of 28.3 percent
  • 9 mg dose: Average weight loss of 25.9 percent
  • 4 mg dose: Average weight loss of 19.0 percent
  • Placebo: Average weight loss of 2.2 percent

On 12 mg, 45.3 percent of participants lost at least 30 percent of their body weight, and waist size fell by 24.1 cm. Lilly has reported four more Phase 3 trials — including 28.7 percent on 12 mg in adults with knee osteoarthritis (TRIUMPH-4) and 20.8 percent in adults with type 2 diabetes (TRIUMPH-2) — and plans to submit retatrutide for U.S. approval in the first quarter of 2027.

Liver Fat Reduction

One of the most clinically significant secondary findings from retatrutide trials has been its effect on hepatic fat content. In an MRI substudy of the Phase 2 obesity trial — 98 adults without diabetes who had at least 10 percent liver fat — retatrutide 12 mg reduced liver fat by 82.4 percent at 24 weeks, and 86 percent of those participants reached normal liver fat (3). Non-alcoholic fatty liver disease (now more accurately called MASLD) affects an estimated 25 percent of adults globally and is a leading driver of cirrhosis and liver transplant need. ### Trial-by-Trial Context

For comparison:

MedicationTrialDurationAverage Weight Loss
Semaglutide 2.4 mgSTEP 168 weeks14.9 percent
Tirzepatide 15 mgSURMOUNT-172 weeks22.5 percent
Retatrutide 12 mgPhase 248 weeks24.2 percent
Retatrutide 12 mgTRIUMPH-1 (Phase 3)80 weeks28.3 percent

Retatrutide achieved greater average weight loss than tirzepatide in a shorter trial, and Phase 3 confirmed it over 80 weeks. These are separate trials; the head-to-head comparison, TRIUMPH-5, is still running.

Retatrutide vs Tirzepatide: Why Patients Are Switching

Patients who have already been through a GLP-1 or dual-agonist protocol ask the same question: is it worth switching to retatrutide? The honest answer is: it depends.

The case for switching: Many patients achieve impressive initial results on tirzepatide but eventually plateau — their weight loss slows or stalls despite continued treatment. Retatrutide adds a third pathway, glucagon, and produced larger average losses in its own trials than tirzepatide did in its trials. Trials have not yet enrolled people switching after a plateau, so we decide it from your history, labs and goals.

The case for staying: If you are achieving strong results on tirzepatide and tolerating it well, switching to retatrutide for a marginal improvement may not be worth the transition. Clinical experience with tirzepatide is substantially longer, and its side effect profile is well-characterized. Retatrutide may have slightly more pronounced GI effects initially due to the triple-agonist mechanism.

The stepping-stone approach: For most patients, we think about medical weight loss as a progression. If you are new to GLP-1 therapy, tirzepatide or semaglutide is usually the right starting point. If you achieve your goal on one of these, continue. If you plateau below your target, retatrutide is the next step we discuss.

Who Is Retatrutide Right For?

Physician and patient discussing next steps after a weight-loss plateau

Based on current clinical data and our experience, retatrutide is most appropriate for:

  • Patients who have plateaued on semaglutide or tirzepatide and want the medication with the largest average losses in trials so far.
  • Patients with significant weight to lose — typically 50 pounds or more. The larger your weight loss target, the more meaningful the incremental advantage retatrutide provides.
  • Patients with fatty liver disease (MASLD/NAFLD) or metabolic syndrome. The hepatic fat reduction data is substantially stronger than for semaglutide or tirzepatide.
  • Patients with insulin resistance or prediabetes who would benefit from comprehensive metabolic effects beyond weight loss alone.

Retatrutide is typically not the right medication for:

  • First-time GLP-1 users — we generally start with tirzepatide.
  • Patients with severe gastrointestinal disorders or active pancreatitis history.
  • Patients with medullary thyroid carcinoma or MEN2 syndrome (a class warning for all GLP-1 agonists).
  • Pregnant or breastfeeding women.

Every protocol at Rewind begins with comprehensive lab work and a detailed clinical assessment to ensure the right medication is matched to the right patient.

Side Effects and What to Expect

Retatrutide’s side effect profile closely resembles tirzepatide’s, with gastrointestinal effects most common during dose escalation:

  • Nausea: Reported by 16 to 43 percent of participants in trials, dose-dependent, most common during dose escalation
  • Diarrhea: Reported by 15 to 25 percent
  • Vomiting: Reported by 8 to 15 percent
  • Constipation: Reported by 6 to 12 percent
  • Decreased appetite: Nearly universal (and considered a therapeutic effect)

Most side effects are transient and improve within two to four weeks at each dose level. Our standard approach minimizes them through gradual titration, adequate hydration, adequate protein intake (0.7 to 1.0 grams per pound of ideal body weight), and patient education about what to expect and when to call us. Rapid escalation is the single most common reason patients struggle with side effects — we do not rush the titration schedule.

Rare but serious risks include pancreatitis, gallbladder disease associated with rapid weight loss, and potential thyroid concerns (a class warning based on rodent studies). These are uncommon but are screened for during initial evaluation and monitored throughout treatment.

Why Most Miami Clinics Don’t Offer Retatrutide

Woman in her fifties laughing with her physician during a follow-up visit at a Miami clinic

Retatrutide is not widely available yet for several reasons:

  1. It is new. Many clinics wait for a branded product before offering a medication.
  2. It requires established pharmacy relationships. Access requires trusted, credentialed pharmacy partners.
  3. Triple-agonist protocols require provider expertise. Dosing, titration, and monitoring differ from single or dual-agonist therapy. Most clinics are still catching up to tirzepatide.
  4. Monitoring requires comprehensive labs. At Rewind, we monitor hepatic function, lipid panel, metabolic markers, and body composition throughout treatment — not just weight.

Rewind offers retatrutide. Our approach is lab-based, supervised, and personalized. We are not a prescribe-and-forget clinic.

Getting Started at Rewind

Every retatrutide protocol at Rewind begins with three things:

  1. Comprehensive metabolic panel and body composition analysis. We establish your baseline — hepatic function, lipids, thyroid, sex hormones, fasting insulin, HOMA-IR, HbA1c, inflammatory markers. Body composition (lean mass, fat mass, visceral fat) is measured so we can track what is actually changing, not just what the scale says.
  2. Clinical assessment and history review. Prior weight loss attempts, prior GLP-1 use, medications, medical history, goals. This determines whether retatrutide is the right choice or whether tirzepatide or another approach makes more sense.
  3. Personalized protocol and titration plan. Your starting dose, escalation schedule, and monitoring cadence are individualized. Protein targets and lifestyle guidance are built around you, not a generic template.

Interested in seeing whether you are a candidate? Take our 2-minute quiz to get a personalized recommendation, or contact us directly to schedule a consultation. If you want to understand our overall approach to weight loss, our medical weight loss page covers every option we offer — from semaglutide and tirzepatide to retatrutide, tesofensine, and peptide-based support.

References

  1. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metab. 2022;34(9):1234.
  2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526.
  3. Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037.
  4. Eli Lilly and Company. TRIUMPH-1 topline results (press release), May 21, 2026.

Ready to see if retatrutide is right for you? Rewind Anti-Aging of Miami offers retatrutide therapy with comprehensive lab-based monitoring and personalized titration. Take our quiz or schedule a consultation →

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Weight loss medications should only be used under the supervision of a qualified healthcare provider. Individual results vary.

Frequently Asked Questions

What is retatrutide and how is it different from semaglutide or tirzepatide?

Retatrutide is a triple incretin receptor agonist that activates three metabolic pathways simultaneously — GLP-1, GIP, and glucagon. Semaglutide activates only GLP-1. Tirzepatide activates GLP-1 and GIP. Adding the glucagon pathway is what makes retatrutide different: it not only suppresses appetite but also promotes fat oxidation in the liver. In a Phase 2 substudy, liver fat fell 82 percent in 24 weeks on the 12 mg dose.

How much weight can you lose on retatrutide?

In the Phase 2 trial published in the New England Journal of Medicine in 2023, participants receiving the 12 mg weekly dose lost an average of 24.2 percent of their body weight over 48 weeks. For a 240 pound individual, that is approximately 58 pounds. 83 percent of participants at that dose lost at least 15 percent. In the 80-week Phase 3 TRIUMPH-1 trial, the 12 mg average reached 28.3 percent, and 45 percent of that group lost at least 30 percent.

Is retatrutide FDA approved?

Not yet. Eli Lilly has reported results from five Phase 3 trials and plans to submit retatrutide for U.S. approval in the first quarter of 2027. Any retatrutide protocol should be managed by a qualified provider with experience monitoring triple-agonist therapy.

Who is retatrutide right for?

Retatrutide is most often considered for patients who have plateaued on semaglutide or tirzepatide, patients with significant weight to lose (50 or more pounds), and patients with fatty liver disease or metabolic syndrome who may benefit from the glucagon pathway's hepatic fat reduction effects. It is typically not the first medication we start with for patients new to GLP-1 therapy — tirzepatide is usually the better starting point.

What are the side effects of retatrutide?

Retatrutide's side effect profile is similar to tirzepatide but can be slightly more pronounced initially due to the triple-agonist mechanism. The most common side effects are nausea, diarrhea, vomiting, constipation, and abdominal discomfort, typically occurring during dose escalation and generally resolving within two to four weeks at each dose level. Gradual titration — the standard clinical approach — significantly reduces the frequency and severity of side effects.

Where can I get retatrutide in Miami?

Retatrutide is not available at most Miami clinics because it requires established pharmacy relationships and provider expertise with triple-agonist protocols. Rewind Anti-Aging of Miami offers retatrutide with comprehensive lab-based monitoring rather than a prescribe-and-forget approach. Your protocol is personalized based on your metabolic data, body composition, and treatment history.

More in weight loss

⚕ Medical Disclaimer

The information on this page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. All treatments at Rewind Anti-Aging of Miami are performed under the supervision of licensed medical professionals. Individual results may vary. Consult your physician before beginning any new treatment protocol.

Meet our clinical team →

Not sure which treatment is right for you?

Take our free 2-minute assessment and get a personalized recommendation.

Take the Quiz →

Take the Next Step

Our team at Rewind Anti-Aging in Miami is here to help you determine if retatrutide therapy is right for your goals.

Chat with Rewind AI

We typically reply instantly

Book
Powered by AI — not medical advice
Book Consultation